ImmunityBio, Inc. IBRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $140.98M+24.4% | $113.29M+37.2% | $82.56M+45.9% | $56.6M+81.3% | $31.22M+112% | ||
| $933K+23.9% | $753K+103% | $371K+91.2% | $194K+234% | $58K— | ||
| $140.04M+24.4% | $112.54M+36.9% | $82.18M+45.7% | $56.41M+81.0% | $31.16M+111% | ||
| 99.3%0.0pp | 99.3%-0.2pp | 99.6%-0.1pp | 99.7%-0.2pp | 99.8%-0.2pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $402.37M+8.9% | $369.32M+7.6% | $343.3M+0.4% | $341.97M-0.8% | $344.64M-4.0% | ||
| -$261.39M-2.1% | -$256.03M+1.8% | -$260.74M+8.6% | -$285.37M+8.9% | -$313.42M+8.9% | ||
| -185.4%+40.6pp | -226%+89.8pp | -315.8%+188pp | -504.2%+500pp | -1,003.8%+1,330pp | ||
| $51.88M+0.7% | $51.54M+1.6% | $50.74M+2.8% | $49.37M+9.3% | $45.19M+13.9% | ||
| -$595.7M-507% | -$98.17M— | —— | —— | —— | ||
| $7.83M+22.3% | $6.41M+21.0% | $5.29M+5.4% | $5.03M-12.8% | $5.76M-27.7% | ||
| -$854.5M-143% | -$351.61M-0.8% | -$348.69M+5.0% | -$367.14M+10.3% | -$409.42M+1.0% | ||
| $108K+180% | -$135K— | $0-100% | $35K+115% | -$234K— | ||
| -$854.53M-143% | -$351.4M-0.8% | -$348.62M+5.0% | -$367.09M+10.3% | -$409.1M+1.1% | ||
| -606.2%-296pp | -310.2%+112pp | -422.3%+226pp | -648.6%+662pp | -1,310.3%+1,494pp | ||
| -$0.85-124% | -$0.38+7.3% | -$0.41+14.6% | -$0.48+17.2% | -$0.58+7.9% | ||
| -$0.85-124% | -$0.38+2.6% | -$0.39+11.4% | -$0.44+18.5% | -$0.54+8.5% | ||
| 3.8B+4.8% | 3.6B+6.5% | 3.4B+7.9% | 3.1B+6.8% | 2.9B+6.5% | ||
| 3.8B+4.8% | 3.6B+6.6% | 3.4B+8.0% | 3.1B+6.9% | 2.9B+6.6% | ||
| —— | —— | —— | —— | —— | ||
| -$237.99M-442% | -$43.94M-15,650% | -$279K-131% | $890K0.0% | $890K-98.0% | ||
| -$8.05M-270% | -$2.17M— | —— | —— | —— | ||
| $140.98M+24.4% | $113.29M+37.2% | $82.56M+45.9% | $56.6M+81.3% | $31.22M+112% | ||
| -$261.39M-2.1% | -$256.03M+1.8% | -$260.74M+8.6% | -$285.37M+8.9% | -$313.42M+8.9% | ||
| -$245.31M-2.0% | -$240.5M+1.8% | -$244.95M+9.0% | -$269.07M+9.3% | -$296.59M+9.2% | ||
| -$245.31M-2.0% | -$240.5M+1.8% | -$244.95M+9.0% | -$269.07M+9.3% | -$296.59M+9.2% | ||
| -174%+38.3pp | -212.3%+84.4pp | -296.7%+179pp | -475.4%+475pp | -949.9%+1,265pp | ||
| -$261.39M-2.1% | -$256.03M+1.8% | -$260.74M+8.6% | -$285.37M+8.9% | -$313.42M+8.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. (IBRX) generated $141.0M in revenue over the trailing twelve months, up 351.5% year over year.
- Is ImmunityBio, Inc. profitable?
- ImmunityBio, Inc. is not currently profitable: it reported a net loss of $854.5M over the trailing twelve months, a -606.2% net margin.
- What are ImmunityBio, Inc.'s profit margins?
- Gross margin is 99.3% and operating margin is -185.4%, with a -606.2% net margin.
- What is ImmunityBio, Inc.'s earnings per share?
- ImmunityBio, Inc.'s diluted EPS over the trailing twelve months is $-0.85.
- Where does ImmunityBio, Inc.'s income statement data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
